Roche offered a glimpse at promising early efficacy data on Thursday morning from a GLP-1/GIP agonist it obtained as part of its $2.7 billion acquisition of Carmot Therapeutics.
In a Phase 1 trial testing CT-388, participants saw a mean placebo-adjusted weight loss of 18.8% at 24…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
